10-K: DBV Technologies Advances Peanut Allergy Patch, Secures Funding

DBV Technologies reports positive Phase 3 VITESSE results for its Viaskin Peanut patch in children aged 4-7, secures significant financing, and outlines accelerated regulatory pathways for both toddler and child populations in the U.S.

Summary

• DBV Technologies is a late-stage biopharmaceutical company developing the Viaskin epicutaneous patch for food allergies.
• Positive topline results from the Phase 3 VITESSE study for the Viaskin Peanut patch in children aged 4-7 years met its primary endpoint with a statistically significant treatment effect (p<0.001) and a 31.8% difference in responder rates between active and placebo arms (95% CI: 24.5%, 39.0%).
• Safety results from VITESSE were consistent with previous trials, showing mild-to-moderate local skin reactions and low rates of discontinuations (3.2% active) and treatment-related anaphylaxis (0.5%).
• For toddlers aged 1-3 years, FDA guidance for an Accelerated Approval pathway for the Viaskin Peanut patch was received, with a confirmatory effectiveness study to be initiated concurrently with the BLA submission.
• The COMFORT Toddlers supplemental safety study for 1-3 year olds has screened its first subject, aiming for approximately 300-350 active treatment subjects to augment safety data to a total of ~600.
• The COMFORT Children supplemental safety study for 4-7 year olds is no longer required, as FDA agreed VITESSE safety data is sufficient for BLA filing.
• BLA submission for the 4-7 year old population is planned for the first half of 2026, potentially accelerating product launch by approximately one year.
• BLA submission for the 1-3 year old population is planned for the second half of 2026, conditional on successful completion of the COMFORT Toddlers study.
• Significant financing was secured in March 2025, including initial gross proceeds of $125.5 million and an additional $195.0 million from warrant exercises in January 2026, triggered by the positive VITESSE results.
• An At-The-Market (ATM) equity program was established in September 2025, raising $65 million in Q4 2025.
• Cash and cash equivalents stood at $194.2 million as of December 31, 2025, with management estimating sufficient liquidity to fund operations into the second quarter of 2027.
• Net loss for 2025 was $146.9 million, an increase from $113.9 million in 2024, primarily due to increased R&D expenses, including pre-commercial inventory build-up.
• The company entered into an updated Manufacturing and Supply Agreement with Sanofi for exclusive Viaskin Peanut API supply and a new Manufacturing and Supply Agreement with FAREVA La Valle for Peanut Source Material (PSM) manufacturing.
• The European MAA for Viaskin Peanut was withdrawn in December 2021 due to EMA concerns, but new scientific advice from EMA in October 2024 indicates a potential path for a 1-7 year old indication with the modified patch, pending a new safety study in toddlers.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, reflecting significant clinical and regulatory progress for Viaskin Peanut, particularly the successful VITESSE trial and clear FDA pathways. The substantial capital raise further de-risks near-term operations and supports commercialization efforts, despite ongoing losses and past regulatory setbacks.

Positives

• Positive topline results from the Phase 3 VITESSE study for Viaskin Peanut patch in children aged 4-7 years, meeting its primary endpoint with a statistically significant treatment effect (p<0.001) and a 31.8% difference in responder rates.
• FDA has agreed to an Accelerated Approval pathway for the Viaskin Peanut patch in toddlers aged 1-3 years, not requiring an additional efficacy study beyond EPITOPE.
• The COMFORT Children supplemental safety study for 4-7 year olds is no longer required, as FDA deemed VITESSE safety data sufficient, potentially accelerating product launch by approximately one year.
• Significant financing secured in March 2025, including $125.5 million initial gross proceeds and an additional $195.0 million from warrant exercises in January 2026, strengthening the company's financial position.
• Cash and cash equivalents of $194.2 million as of December 31, 2025, with estimated liquidity to fund operations into Q2 2027.
• Long-term efficacy and safety demonstrated in the EPOPEX study for toddlers, with 83.5% of participants reaching an ED of 1000 mg after three years and no treatment-related anaphylaxis in Year 3.
• Manufacturing and supply agreements updated with Sanofi for API and FAREVA La Valle for PSM, securing commercial-scale capacity.
• Net loss per share improved to $(1.05) in 2025 from $(1.17) in 2024, despite increased net loss.

Negatives

• The company incurred significant net losses of $146.9 million in 2025, increasing from $113.9 million in 2024, and has an accumulated deficit of $1,553 million.
• Operating expenses increased by 26% to $152.7 million in 2025, driven by R&D and pre-commercial inventory build-up.
• The company remains dependent on additional funding, which may not be available on acceptable terms or at all, posing a risk to product development and commercialization efforts.
• The European MAA for Viaskin Peanut was withdrawn in December 2021 due to EMA concerns regarding data limitations and effect size from a single pivotal study, requiring a new safety study in toddlers with the modified patch for future resubmission.
• The previous BLA submission for 4-11 year olds in the U.S. received a Complete Response Letter (CRL) in 2020, citing concerns about patch adhesion and requiring additional CMC data and human factors studies.
• The Accelerated Approval pathway for toddlers requires a post-marketing confirmatory study, which, if unsuccessful, could lead to withdrawal of approval.
• The company faces substantial competition from other pharmaceutical and biotechnology companies with greater resources and experience in the food allergy space.
• Palforzia, a competing peanut allergy treatment, is being discontinued by Stallergenes Greer on July 31, 2026, which could indicate challenges in the market or for OIT.

Risks

• Significant and anticipated continued losses, requiring substantial additional funding which may not be available on acceptable terms.
• Limitations under French law on raising additional share capital, potentially hindering funding.
• Risk of internal controls over financial reporting being ineffective, affecting investor confidence.
• Almost entire dependence on successful development and commercialization of Viaskin technology, with high risk of failure in clinical trials.
• Oral food challenge procedures in clinical trials can trigger severe or life-threatening allergic reactions, potentially delaying or halting trials.
• Delays, suspensions, or terminations in clinical trials due to various factors (e.g., safety, efficacy, manufacturing, regulatory changes, subject enrollment) could increase costs and delay revenue generation.
• Failure to obtain regulatory approval from FDA or comparable foreign authorities would prevent commercialization.
• Regulatory approvals, if obtained, may have limitations on marketing, patient population, or require warnings, impairing revenue generation.
• Post-marketing restrictions, withdrawal from market, or substantial penalties for non-compliance or unanticipated problems after approval.
• Failure to meet projected development and commercialization goals in announced timeframes could delay commercialization and harm business.
• Access to raw materials and products for clinical trials and commercial manufacturing is not guaranteed, and reliance on single-source third-party manufacturers (Sanofi for API, FAREVA for patches) poses risks of delays or supply interruptions.
• Lack of commercial-ready marketing and sales infrastructure, requiring significant investment and posing risks if not effectively established or if third-party arrangements are unsuccessful.
• Product candidates regulated as biologics, potentially subject to biosimilar competition sooner than anticipated (e.g., 12-year exclusivity could be shortened).
• Undesirable side effects from product candidates could delay/prevent approval, limit commercial profile, or lead to negative consequences post-approval.
• Changes in regulatory requirements or guidance (e.g., EU Clinical Trials Regulation, Pharma Package) could increase costs, delay timelines, or reduce market exclusivity.
• Failure to secure collaborations with strategic partners for product candidates outside food allergies could limit development and revenue.
• Inadequate protection or enforcement of intellectual property rights could decline competitiveness.
• Complex legal and factual questions in biopharmaceutical patents, potentially impacting patent position.
• Inability to protect intellectual property rights in all jurisdictions or enforce them adequately.
• Failure to maintain confidentiality of trade secrets could harm business and competitive position.
• Risk of employees engaging in misconduct, including violating regulatory standards or insider trading.
• Product liability and other lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential.
• Volatility in market price of ordinary shares and ADSs, potentially due to factors unrelated to operating performance.
• Concentrated share ownership by principal shareholders and management, influencing corporate decisions.
• Risk of delisting from Nasdaq if continued listing requirements are not met.
• Limitations on dividend payments and preferential subscription rights for ADS holders.
• French foreign investment control procedures for critical technologies (biotechnologies) may limit non-French investors.
• Difficulty for U.S. investors to enforce civil liabilities against the company and non-U.S. directors/management.
• Differences in shareholder rights under French corporate law compared to U.S. law.
• Exposure to significant foreign exchange risk due to U.S. dollar-denominated operations and supplies.
• Climate change, extreme weather events, and evolving sustainability regulations could disrupt third-party operations and increase costs.
• Use of hazardous chemicals and biological materials, with claims relating to improper handling being costly.
• Stringent and changing data privacy and security obligations (GDPR, CCPA), with potential for regulatory actions, litigation, and reputational harm from non-compliance or security incidents.
• Potential for adverse consequences if information technology systems or sensitive information are compromised.
• Risks associated with future acquisitions or strategic alliances, including integration difficulties and failure to realize benefits.
• Impact of international trade policies (tariffs, sanctions) on supply chain and costs.
• Difficulties in managing growth and transitioning to a commercial-stage organization.

Future Outlook

The company anticipates submitting a Biologics License Application (BLA) for the Viaskin Peanut patch in children aged 4-7 years in the first half of 2026, potentially accelerating product launch by approximately one year, subject to FDA approval. For toddlers aged 1-3 years, a BLA submission under the Accelerated Approval program is planned for the second half of 2026, contingent on the successful completion of the COMFORT Toddlers supplemental safety study and the initiation of a post-marketing confirmatory effectiveness study in parallel with commercialization. The company also intends to resubmit its Marketing Authorization Application (MAA) in Europe for a 1-7 year old indication once new safety data from a modified patch toddler study is available. Management estimates that existing cash and cash equivalents, combined with recent financing proceeds, are sufficient to fund operations into the second quarter of 2027.

Management Comments

• As we enter 2026, our focus shifts toward commercialization and laying the groundwork to transform the lives of children living with peanut allergy.
• The Company has proven our ability to perform under pressure and achieve key results, as seen in the announcement of the positive topline results of the VITESSE clinical study and successful financing.
• The Company's goal is to broaden FDA-approved options for pediatric peanut allergy while delivering value to stakeholders.

Industry Context

StockSavvy.ai notes that the discontinuation of Palforzia (oral immunotherapy) by Stallergenes Greer in July 2026 creates a significant void in the peanut allergy treatment market, potentially reducing direct competition for DBV Technologies' Viaskin Peanut patch if approved. However, the recent FDA approval of Xolair (omalizumab), an anti-IgE antibody, for food allergy reduction, and GlaxoSmithKline's development of ozureprubart (an IgE-pathway inhibitor with Phase IIb readout expected in 2027), indicate a dynamic and evolving competitive landscape. While Viaskin's epicutaneous immunotherapy (EPIT) offers a differentiated, non-invasive approach with a favorable safety profile, it will need to demonstrate compelling advantages in efficacy, convenience, and long-term benefits to capture market share against emerging and existing therapies, particularly given the ongoing need for strict allergen avoidance with current treatments.

Comparison to Industry Standards

• The positive VITESSE Phase 3 results (31.8% difference in responder rates) for Viaskin Peanut in 4-7 year olds compare favorably to the efficacy demonstrated by Palforzia (oral immunotherapy), which showed a 12.4% difference in responder rates in its pivotal trial (PALISADE).
• The safety profile of Viaskin Peanut, characterized by mild-to-moderate local skin reactions and low rates of systemic adverse events and anaphylaxis (0.5% in VITESSE), appears to offer a more favorable tolerability profile compared to oral immunotherapies like Palforzia, which historically had higher rates of systemic reactions and epinephrine use.
• The FDA's Accelerated Approval pathway for toddlers (1-3 years) for Viaskin Peanut, based on the EPITOPE study's efficacy and additional safety data, positions DBV to potentially address a critical unmet need in a younger population where few approved treatments exist.
• The discontinuation of Palforzia by Stallergenes Greer by July 2026 removes a direct competitor, but the recent FDA approval of Xolair (omalizumab) for food allergy reduction (including peanut) in patients aged 1 year and older introduces a new, non-allergen-specific therapeutic option that could compete for market share.
• GlaxoSmithKline's ozureprubart, an IgE-pathway inhibitor with Phase IIb results expected in 2027, represents a future competitive threat, potentially offering a different mechanism of action for food allergy treatment.

Management Changes

Corporate Governance

Legal Proceedings

• A class action complaint filed on January 15, 2019, alleging violations of federal securities laws, was dismissed with prejudice on July 29, 2022.
• Not currently subject to any material legal proceedings.

Related Party Transactions

• Compensation to Directors and Officers totaled $14.4 million in 2025, up from $8.5 million in 2024.
• Amounts payable to related parties were $3.087 million as of December 31, 2025, compared to $1.635 million in 2024.
• The parent company has a cashpooling agreement with its subsidiaries, with loans & advances amounting to $1.8 million in 2025.
• No other significant related-party transactions were identified.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical results, accelerated regulatory pathways, and strengthened financial position. However, continued losses and potential future dilution from capital raises remain risks. French corporate law and foreign investment controls may affect certain shareholder rights and investment opportunities.
• Patients (Peanut Allergy): Significant positive impact with the potential for a new, safe, and effective epicutaneous immunotherapy (Viaskin Peanut patch) for both toddlers (1-3 years) and children (4-7 years), addressing a high unmet medical need, especially given the discontinuation of a competing product (Palforzia).
• Caregivers: The non-invasive, self-administered nature of the Viaskin patch could significantly improve the quality of life for parents and caregivers by reducing anxiety and fear of accidental peanut ingestion.
• Employees: Growth in full-time employees, particularly in Medical Affairs, Quality, Regulatory, HR, IS, Finance, and Legal/Compliance, indicates job creation and expansion as the company transitions towards commercialization. Equity incentive plans aim to attract and retain talent.
• Regulatory Authorities (FDA, EMA): Ongoing dialogue and alignment on regulatory pathways demonstrate active engagement and progress towards approvals, but also highlight the rigorous review process and potential for further requirements.
• Third-Party Manufacturers/CROs: Continued reliance on and engagement with third-party manufacturers (Sanofi, FAREVA) and CROs (SYNEOS, ICON, Advanced Clinical) for API supply, patch manufacturing, and clinical trial conduct, indicating ongoing business for these partners.

Next Steps

• Submit Biologics License Application (BLA) for Viaskin Peanut patch in children aged 4-7 years in the first half of 2026.
• Initiate the confirmatory effectiveness study for Viaskin Peanut patch in 1-3 year olds by the time of BLA submission, to run in parallel to commercialization.
• Complete the COMFORT Toddlers supplemental safety study for 1-3 year olds.
• Submit Biologics License Application (BLA) for Viaskin Peanut patch in toddlers aged 1-3 years in the second half of 2026.
• Plan for a new safety study in toddlers (1-3 years) with the modified patch to support a future Marketing Authorization Application (MAA) resubmission in Europe for a 1-7 year old indication.
• Continue to build commercial-ready marketing and sales infrastructure in North America and the European Union.
• Advance clinical development of additional Viaskin product candidates, including Viaskin Milk.
• Further develop the manufacturing process for product candidates and secure redundancy in the supply chain.
• Monitor and adapt to evolving regulatory requirements and industry trends.

Key Dates

Recommendation

The filing presents compelling evidence of significant progress in DBV Technologies' core Viaskin Peanut program, with positive Phase 3 VITESSE results and a clear, accelerated FDA pathway for both toddler and child populations. The substantial capital raise provides a solid financial runway, mitigating immediate liquidity concerns. While the company still faces commercialization challenges and ongoing losses, the clinical efficacy, favorable safety profile, and the impending market void left by a competitor's discontinuation position DBV for strong potential growth and market penetration. This progress, coupled with a differentiated product, suggests a favorable risk-reward profile for long-term investors.

Keywords

Viaskin Peanut Patch, Peanut Allergy, Epicutaneous Immunotherapy, EPIT, FDA Approval, BLA Submission, Clinical Trials, VITESSE Study, EPITOPE Study, COMFORT Toddlers, Accelerated Approval, Biologics, Biopharmaceutical, Food Allergy Treatment, Immunotherapy, Drug Development, Regulatory Pathway, Financial Results, Capital Raise, Nasdaq, Euronext Paris, Sanofi, FAREVA, Intellectual Property, Risk Management, Corporate Governance, Healthcare Regulation, Data Privacy